New directions in nicotine vaccine design and use

Advances in Pharmacology

Volumn 69, Issue , 2014, Pages 553-580

  Pentel, Paul R ^a,b,c   LeSage, Mark G ^a,b,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Addiction; Immunogen; Immunotherapy; Nicotine; Vaccine

Indexed keywords

ANTIGEN; CARRIER PROTEIN; HAPTEN; IMMUNOLOGICAL ADJUVANT; LIPOSOME; NANOPARTICLE; NICOTINE; NICOTINE VACCINE; PHOSPHORYL LIPID A;

AMINO ACID SEQUENCE; ANTIBODY AFFINITY; ANTIBODY BLOOD LEVEL; ANTIBODY COMBINING SITE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; GENE TRANSFER; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; NONHUMAN; PASSIVE IMMUNIZATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SMOKING CESSATION; T LYMPHOCYTE; TOBACCO; TOBACCO DEPENDENCE; VACCINATION;

EID: 84893176616     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-420118-7.00014-7     Document Type: Chapter

References (85)

1. Anon The health consequences of smoking: Nicotine addiction, a report of the Surgeon General 1988, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Office on Smoking and Health, Atlanta, GA.
2. Anon Trial watch: Xenova's TA-NIC vaccine shows promise. Expert Review of Vaccines 2004, 3:386.
3. Awate S., Babiuk L.A., Mutwiri G. Mechanisms of action of adjuvants. Frontiers in Immunology 2013, 4:114.
4. Bevins R.A., Wilkinson J.L., Sanderson S.D. Vaccines to combat smoking. Expert Opinion on Biological Therapy 2008, 8:379-383.
5. Bremer P.T., Janda K.D. Investigating the effects of a hydrolytically stable hapten and a Th1 adjuvant on heroin vaccine performance. Journal of Medicinal Chemistry 2012, 55:10776-10780.
6. Brimijoin S., Shen X., Orson F., Kosten T. Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse. Expert Review of Vaccines 2013, 12:323-332.
7. Brody A.L., Mandelkern M.A., Costello M.R., Abrams A.L., Scheibal D., Farahi J., et al. Brain nicotinic acetylcholine receptor occupancy: Effect of smoking a denicotinized cigarette. The International Journal of Neuropsychopharmacology 2009, 12:305-316.
8. Cai X., Tsuchikama K., Janda K.D. Modulating cocaine vaccine potency through hapten fluorination. Journal of the American Chemical Society 2013, 135:2971-2974.
9. Cao J., Belluzzi J.D., Loughlin S.E., Keyler D.E., Pentel P.R., Leslie F.M. Acetaldehyde, a major constituent of tobacco smoke, enhances behavioral, endocrine, and neuronal responses to nicotine in adolescent and adult rats. Neuropsychopharmacology 2007, 32:2025-2035.
10. Carrera M.R., Ashley J.A., Hoffman T.Z., Isomura S., Wirsching P., Koob G.F., et al. Investigations using immunization to attenuate the psychoactive effects of nicotine. Bioorganic and Medicinal Chemistry 2004, 12:563-570.
11. Cerny E.H., Levy R., Mauel J., Mpandi M., Mutter M., Henzelin-Nkubana C., et al. Preclinical development of a vaccine 'against smoking'. Onkologie 2002, 25:406-411.
12. Chen X., Pravetoni M., Bhayana B., Pentel P.R., Wu M.X. High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants. Vaccine 2012, 31:159-164.
13. Clemens K.J., Caille S., Stinus L., Cador M. The addition of five minor tobacco alkaloids increases nicotine-induced hyperactivity, sensitization and intravenous self-administration in rats. The International Journal of Neuropsychopharmacology 2009, 12:1355-1366.
14. ClinicalTrials.gov Safety study of Ch-mAb7F9 for methamphetamine abuse http://clinicaltrialsgov/ct2/show/NCT01603147?term=methamphetamine+antibody&rank=4.
15. Cornish K.E., Harris A.C., LeSage M.G., Keyler D.E., Burroughs D., Earley C., et al. Combined active and passive immunization against nicotine: Minimizing monoclonal antibody requirements using a target antibody concentration strategy. International Immunopharmacology 2011, 11:1809-1815.
16. Cornuz J., Zwahlen S., Jungi W.F., Osterwalder J., Klingler K., van Melle G., et al. A vaccine against nicotine for smoking cessation: A randomized controlled trial. PLoS One 2008, 3:e2547.
17. Crothers K., Daly K.R., Rimland D., Goetz M.B., Gibert C.L., Butt A.A., et al. Decreased serum antibody responses to recombinant pneumocystis antigens in HIV-infected and uninfected current smokers. Clinical and Vaccine Immunology 2011, 18:380-386.
18. Damaj M.I., Grabus S.D., Navarro H.A., Vann R.E., Warner J.A., King L.S., et al. Effects of hydroxymetabolites of bupropion on nicotine dependence behavior in mice. Journal of Pharmacology and Experimental Therapeutics 2010, 334:1087-1095.
19. De B.P., Pagovich O.E., Hicks M.J., Rosenberg J.B., Moreno A.Y., Janda K.D., et al. Disrupted adenovirus-based vaccines against small addictive molecules circumvent anti-adenovirus immunity. Human Gene Therapy 2013, 24:58-66.
20. de Villiers S.H., Cornish K.E., Troska A.J., Pravetoni M., Pentel P.R. Increased efficacy of a trivalent nicotine vaccine compared to a dose-matched monovalent vaccine when formulated with alum. Vaccine 2013, 31:6185-6193.
21. de Villiers S.H., Lindblom N., Kalayanov G., Gordon S., Baraznenok I., Malmerfelt A., et al. Nicotine hapten structure, antibody selectivity and effect relationships: Results from a nicotine vaccine screening procedure. Vaccine 2010, 28:2161-2168.
22. Esterlis I., Hannestad J.O., Perkins E., Bois F., D'Souza D.C., Tyndale R.F., et al. Effect of a nicotine vaccine on nicotine binding to beta2*-nicotinic acetylcholine receptors in vivo in human tobacco smokers. The American Journal of Psychiatry 2013, 170:399-407.
23. Fahim R.E., Kessler P.D., Kalnik M.W. Therapeutic vaccines against tobacco addiction. Expert Review of Vaccines 2013, 12:333-342.
24. Finklea J.F., Hasselblad V., Riggan W.B., Nelson W.C., Hammer D.I., Newill V.A. Cigarette smoking and hemagglutination inhibition response to influenza after natural disease and immunization. American Review of Respiratory Disease 1971, 104:368-376.
25. Fox B.S., Kantak K.M., Edwards M.A., Black K.M., Bollinger B.K., Botka A.J., et al. Efficacy of a therapeutic cocaine vaccine in rodent models. Nature Medicine 1996, 2:1129-1132.
26. Gelal A., Balkan D., Ozzeybek D., Kaplan Y.C., Gurler S., Guven H., et al. Effect of menthol on the pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. European Journal of Clinical Pharmacology 2005, 60:785-790.
27. Gentry W.B., Laurenzana E.M., Williams D.K., West J.R., Berg R.J., Terlea T., et al. Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats. International Immunopharmacology 2006, 6:968-977.
28. George T.P., Weinberger A.H. Monoamine oxidase inhibition for tobacco pharmacotherapy. Clinical Pharmacology and Therapeutics 2008, 83:619-621.
29. Han D., Pal S., Nangreave J., Deng Z., Liu Y., Yan H. DNA origami with complex curvatures in three-dimensional space. Science 2011, 332:342-346.
30. Hardin J.S., Wessinger W.D., Wenger G.R., Proksch J.W., Laurenzana E.M., Owens S.M. A single dose of monoclonal anti-phencyclidine IgG offers long-term reductions in phencyclidine behavioral effects in rats. Journal of Pharmacology and Experimental Therapeutics 2002, 302:119-126.
31. Hartmann-Boyce J., Cahill K., Hatsukami D., Cornuz J. Nicotine vaccines for smoking cessation. Cochrane Database of Systematic Reviews 2012, 8. CD007072.
32. Hatsukami D.K., Jorenby D.E., Gonzales D., Rigotti N.A., Glover E.D., Oncken C.A., et al. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clinical Pharmacology and Therapeutics 2011, 89:392-399.
33. Hatsukami D.K., Rennard S., Jorenby D., Fiore M., Koopmeiners J., de Vos A., et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clinical Pharmacology and Therapeutics 2005, 78:456-467.
34. Hicks M.J., Rosenberg J.B., De B.P., Pagovich O.E., Young C.N., Qiu J.P., et al. AAV-directed persistent expression of a gene encoding anti-nicotine antibody for smoking cessation. Science Translational Medicine 2012, 4:140ra87.
35. Hieda Y., Keyler D.E., Ennifar S., Fattom A., Pentel P.R. Vaccination against nicotine during continued nicotine administration in rats: Immunogenicity of the vaccine and effects on nicotine distribution to brain. International Journal of Immunopharmacology 2000, 22:809-819.
36. Hoogsteder P.H., Kotz D., van Spiegel P.I., Viechtbauer W., Brauer R., Kessler P.D., et al. The efficacy and safety of a nicotine conjugate vaccine (NicVAX(R)) or placebo co-administered with varenicline (Champix(R)) for smoking cessation: Study protocol of a phase IIb, double blind, randomized, placebo controlled trial. BMC Public Health 2012, 12:1052.
37. Isomura S., Wirsching P., Janda K.D. An immunotherapeutic program for the treatment of nicotine addiction: Hapten design and synthesis. Journal of Organic Chemistry 2001, 66:4115-4121.
38. Kasturi S.P., Skountzou I., Albrecht R.A., Koutsonanos D., Hua T., Nakaya H.I., et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011, 470:543-547.
39. Keyler D.E., Roiko S.A., Benlhabib E., LeSage M.G., St Peter J.V., Stewart S., et al. Monoclonal nicotine-specific antibodies reduce nicotine distribution to brain in rats: Dose- and affinity-response relationships. Drug Metabolism and Disposition 2005, 33:1056-1061.
40. Keyler D.E., Roiko S.A., Earley C.A., Murtaugh M.P., Pentel P.R. Enhanced immunogenicity of a bivalent nicotine vaccine. International Immunopharmacology 2008, 8:1589-1594.
41. Kishimoto K., Altreuter D., Johnston L., Keller P., Pittet L. SEL-068 A fully synthetic nanoparticle vaccine for smoking cessation and relapse prevention 2012.
42. Klinman D.M., Klaschik S., Sato T., Tross D. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Advanced Drug Delivery Reviews 2009, 61:248-255.
43. Kosten T.R., Gonsai K., St Clair Roberts J., Jack L., Bond J., Mitchell E., et al. Phase II human study of cocaine vaccine TA-CD 2002.
44. La Montagne J.R., Fauci A.S. Intradermal influenza vaccination-Can less be more?. New England Journal of Medicine 2004, 351:2330-2332.
45. Le Foll B., Chakraborty-Chatterjee M., Lev-Ran S., Barnes C., Pushparaj A., Gamaleddin I., et al. Varenicline decreases nicotine self-administration and cue-induced reinstatement of nicotine-seeking behaviour in rats when a long pretreatment time is used. The International Journal of Neuropsychopharmacology 2012, 15:1265-1274.
46. LeSage M.G., Keyler D.E., Collins G., Pentel P.R. Effects of continuous nicotine infusion on nicotine self-administration in rats: Relationship between continuously infused and self-administered nicotine doses and serum concentrations. Psychopharmacology 2003, 170:278-286.
47. LeSage M.G., Keyler D.E., Hieda Y., Collins G., Burroughs D., Le C., et al. Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine self-administration in rats. Psychopharmacology 2006, 184:409-416.
48. LeSage M.G., Keyler D.E., Pentel P.R. Current status of immunologic approaches to treating tobacco dependence: Vaccines and nicotine-specific antibodies. The AAPS Journal 2006, 8:E65-E75.
49. LeSage M.G., Shelley D., Pravetoni M., Pentel P.R. Enhanced attenuation of nicotine discrimination in rats by combining nicotine-specific antibodies with a nicotinic receptor antagonist. Pharmacology, Biochemistry, and Behavior 2012, 102:157-162.
50. Lindblom N., de Villiers S.H., Kalayanov G., Gordon S., Johansson A.M., Svensson T.H. Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration; International Review of Thoracic Diseases 2002, 69:254-260.
51. Lindblom N., de Villiers S.H., Semenova S., Kalayanov G., Gordon S., Schilstrom B., et al. Active immunisation against nicotine blocks the reward facilitating effects of nicotine and partially prevents nicotine withdrawal in the rat as measured by dopamine output in the nucleus accumbens, brain reward thresholds and somatic signs. Archives of Pharmacology 2005, 372:182-194.
52. Liu X., Xu Y., Yu T., Clifford C., Liu Y., Yan H., et al. A DNA nanostructure platform for directed assembly of synthetic vaccines. Nano Letters 2012, 12:4254-4259.
53. Lockner J.W., Ho S.O., McCague K.C., Chiang S.M., Do T.Q., Fujii G., et al. Enhancing nicotine vaccine immunogenicity with liposomes. Bioorganic & Medicinal Chemistry Letters 2013, 23:975-978.
54. Matyas G.R., Mayorov A.V., Rice K.C., Jacobson A.E., Cheng K., Iyer M.R., et al. Liposomes containing monophosphoryl lipid A: A potent adjuvant system for inducing antibodies to heroin hapten analogs. Vaccine 2013, 31:2804-2810.
55. Maurer P., Jennings G.T., Willers J., Rohner F., Lindman Y., Roubicek K., et al. A therapeutic vaccine for nicotine dependence: Preclinical efficacy, and Phase I safety and immunogenicity. European Journal of Immunology 2005, 35:2031-2040.
56. McCluskie M.J., Pryde D.C., Gervais D.P., Stead D.R., Zhang N., Benoit M., et al. Enhancing immunogenicity of a 3'aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates. International Immunopharmacology 2013, 16:50-56.
57. McHeyzer-Williams L.J., McHeyzer-Williams M.G. Antigen-specific memory B cell development. Annual Review of Immunology 2005, 23:487-513.
58. Migone T.S., Subramanian G.M., Zhong J., Healey L.M., Corey A., Devalaraja M., et al. Raxibacumab for the treatment of inhalational anthrax. The New England Journal of Medicine 2009, 361:135-144.
59. Mingozzi F., High K.A. Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges. Nature Reviews. Genetics 2011, 12:341-355.
60. Moreno A.Y., Azar M.R., Koob G.F., Janda K.D. Probing the protective effects of a conformationally constrained nicotine vaccine. Vaccine 2012, 30:6665-6670.
61. Moreno A.Y., Azar M.R., Warren N.A., Dickerson T.J., Koob G.F., Janda K.D. A critical evaluation of a nicotine vaccine within a self-administration behavioral model. Molecular Pharmaceutics 2010, 7:431-441.
62. Orson F.M., Kinsey B.M., Singh R.A., Wu Y., Gardner T., Kosten T.R. The future of vaccines in the management of addictive disorders. Current Psychiatry Reports 2007, 9:381-387.
63. Orson F.M., Rossen R.D., Shen X., Lopez A.Y., Wu Y., Kosten T.R. Spontaneous development of IgM anti-cocaine antibodies in habitual cocaine users: Effect on IgG antibody responses to a cocaine cholera toxin B conjugate vaccine. The American Journal on Addictions 2013, 22:169-174.
64. Pape K.A., Taylor J.J., Maul R.W., Gearhart P.J., Jenkins M.K. Different B cell populations mediate early and late memory during an endogenous immune response. Science 2011, 331:1203-1207.
65. Peek L.J., Middaugh C.R., Berkland C. Nanotechnology in vaccine delivery. Advanced Drug Delivery Reviews 2008, 60:915-928.
66. Pentel P.R., Dufek M.B., Roiko S.A., Lesage M.G., Keyler D.E. Differential effects of passive immunization with nicotine-specific antibodies on the acute and chronic distribution of nicotine to brain in rats. The Journal of Pharmacology and Experimental Therapeutics 2006, 317:660-666.
67. Pentel P.R., Malin D.H., Ennifar S., Hieda Y., Keyler D.E., Lake J.R., et al. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacology, Biochemistry, and Behavior 2000, 65:191-198.
68. Pravetoni M., Keyler D.E., Pidaparthi R.R., Carroll F.I., Runyon S.P., Murtaugh M.P., et al. Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities. Biochemical Pharmacology 2012, 83:543-550.
69. Pravetoni M., Keyler D.E., Raleigh M.D., Harris A.C., Lesage M.G., Mattson C.K., et al. Vaccination against nicotine alters the distribution of nicotine delivered via cigarette smoke inhalation to rats. Biochemical Pharmacology 2011, 81:1164-1170.
70. Presta L.G. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Advanced Drug Delivery Reviews 2006, 58:640-656.
71. Raupach T., Hoogsteder P.H., Onno van Schayck C.P. Nicotine vaccines to assist with smoking cessation: Current status of research. Drugs 2012, 72:e1-e16.
72. Roiko S.A., Harris A.C., Keyler D.E., Lesage M.G., Zhang Y., Pentel P.R. Combined active and passive immunization enhances the efficacy of immunotherapy against nicotine in rats. Journal of Pharmacology and Experimental Therapeutics 2008, 325:985-993.
73. Roiko S.A., Harris A.C., LeSage M.G., Keyler D.E., Pentel P.R. Passive immunization with a nicotine-specific monoclonal antibody decreases brain nicotine levels but does not precipitate withdrawal in nicotine-dependent rats. Pharmacology, Biochemistry, and Behavior 2009, 93:105-111.
74. Roseman C., Truedsson L., Kapetanovic M.C. The effect of smoking and alcohol consumption on markers of systemic inflammation, immunoglobulin levels and immune response following pneumococcal vaccination in patients with arthritis. Arthritis Research and Therapy 2012, 14:R170.
75. Rudra J.S., Tian Y.F., Jung J.P., Collier J.H. A self-assembling peptide acting as an immune adjuvant. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:622-627.
76. Sanderson S.D., Cheruku S.R., Padmanilayam M.P., Vennerstrom J.L., Thiele G.M., Palmatier M.I., et al. Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant. International Immunopharmacology 2003, 3:137-146.
77. Satoskar S.D., Keyler D.E., LeSage M.G., Raphael D.E., Ross C.A., Pentel P.R. Tissue-dependent effects of immunization with a nicotine conjugate vaccine on the distribution of nicotine in rats. International Immunopharmacology 2003, 3:957-970.
78. Shen X.Y., Orson F.M., Kosten T.R. Vaccines against drug abuse. Clinical Pharmacology and Therapeutics 2012, 91:60-70.
79. Spreafico R., Ricciardi-Castagnoli P., Mortellaro A. The controversial relationship between NLRP3, alum, danger signals and the next-generation adjuvants. European Journal of Immunology 2010, 40:638-642.
80. Taylor J.J., Jenkins M.K., Pape K.A. Heterogeneity in the differentiation and function of memory B cells. Trends in Immunology 2012, 33:590-597.
81. Tonstad S., Heggen E., Giljam H., Lagerback P.A., Tonnesen P., Wikingsson L.D., et al. Niccine(R), a nicotine vaccine, for relapse prevention: A Phase II, randomized, placebo-controlled, multicenter clinical trial. Nicotine & Tobacco Research 2013, 15(9):1492-1501.
82. Waldmann T.A., Strober W. Metabolism of immunoglobulins. Progress in Allergy 1969, 13:1-110.
83. Wilson-Welder J.H., Torres M.P., Kipper M.J., Mallapragada S.K., Wannemuehler M.J., Narasimhan B. Vaccine adjuvants: Current challenges and future approaches. Journal of Pharmaceutical Sciences 2009, 98:1278-1316.
84. Winter A.P., Follett E.A., McIntyre J., Stewart J., Symington I.S. Influence of smoking on immunological responses to hepatitis B vaccine. Vaccine 1994, 12:771-772.
85. Zaman M., Good M.F., Toth I. Nanovaccines and their mode of action. Methods 2013, 60:226-231.